Iberdomide
Iberdomide is an experimental thalidomide analog that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers and was also tested in people with lupus.
Iberdomide has been tested in combination with Bi-specific T-cell engagers in the B-Cell Non-Hodgkin Lymphoma setting, but has been dropped in favor of golcadomide.